Savara Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Savara Inc. has filed its 2023 10-K report, detailing financial data and historical corporate changes.</b>

AI Summary

Savara Inc (SVRA) filed a Annual Report (10-K) with the SEC on March 7, 2024. Savara Inc. filed its 10-K report for the fiscal year ending December 31, 2023. The company was formerly known as Mast Therapeutics, Inc., ADVENTRX PHARMACEUTICALS INC, and BIOKEYS PHARMACEUTICALS INC. The filing includes data related to various stock option plans, including the TwoThousandAndEight Stock Option Plan and the TwoThousandAndFifteen Omnibus Incentive Plan. Financial data points such as Accumulated Net Unrealized Investment Gain/Loss and Additional Paid In Capital are detailed for fiscal years 2022 and 2023. The report references a Loan and Security Agreement with Silicon Valley Bank dated April 21, 2022.

Why It Matters

For investors and stakeholders tracking Savara Inc, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Savara Inc.'s financial health, operational details, and strategic positioning for the fiscal year 2023. Understanding the historical corporate name changes and the specifics of various stock option plans offers insight into the company's evolution and employee incentive structures.

Risk Assessment

Risk Level: medium — Savara Inc shows moderate risk based on this filing. The company's financial disclosures are extensive, but specific revenue and profitability figures for the current fiscal year are not immediately available in this header data, suggesting a need to review the full filing for a complete picture.

Analyst Insight

Review the full 10-K filing to analyze Savara Inc.'s revenue, net income, and debt-to-equity ratio for fiscal year 2023 to assess its financial performance and outlook.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed Period of Report)
• 2024-03-07 — Filing Date (Filed as of Date)
• 0000950170-24-027920 — Accession Number (Unique identifier for the filing)
• 001-32157 — SEC File Number (SEC filing identifier)

Key Players & Entities

• Savara Inc. (company) — Filer name
• Mast Therapeutics, Inc. (company) — Former company name
• ADVENTRX PHARMACEUTICALS INC (company) — Former company name
• BIOKEYS PHARMACEUTICALS INC (company) — Former company name
• Silicon Valley Bank (company) — Bank involved in a loan agreement
• Evercore Group LLC (company) — Entity mentioned in relation to dates
• Internal Revenue Service (regulator) — Tax authority
• Texas (location) — State of incorporation and business address

FAQ

Industry Context

Savara Inc. operates in the Pharmaceutical Preparations industry (SIC code 2834).

Regulatory Implications

The filing is a Form 10-K, a mandatory annual report required by the U.S. Securities and Exchange Commission (SEC) for public companies.

What Investors Should Do

1. Analyze the full 10-K for detailed financial statements, including revenue, expenses, and cash flow.
2. Investigate the company's product pipeline and any updates on clinical trials or regulatory approvals mentioned in the filing.
3. Assess the company's debt structure and cash position as detailed in the financial statements.

Key Dates

• 2023-12-31: Fiscal Year End — Marks the end of the reporting period for the 10-K.
• 2024-03-07: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial analysis of the 2023 10-K filing; comparison to prior filings will require accessing those documents.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share SVRA The Nasdaq Global Se
• $1.00 m — ued listing requirements, including the $1.00 minimum closing bid price requirement, ou

Filing Documents

• svra-20231231.htm (10-K) — 2224KB
• svra-ex10_36.htm (EX-10.36) — 97KB
• svra-ex23_1.htm (EX-23.1) — 3KB
• svra-ex31_1.htm (EX-31.1) — 13KB
• svra-ex31_2.htm (EX-31.2) — 13KB
• svra-ex32_1.htm (EX-32.1) — 11KB
• svra-ex97.htm (EX-97) — 28KB
• img198116697_0.jpg (GRAPHIC) — 5KB
• img198116697_1.jpg (GRAPHIC) — 31KB
• img198116697_2.jpg (GRAPHIC) — 35KB
• 0000950170-24-027920.txt (&nbsp;) — 10182KB
• svra-20231231.xsd (EX-101.SCH) — 1526KB
• svra-20231231_htm.xml (XML) — 1687KB

Business

Business 5 Item 1A.

Risk Factors

Risk Factors 26 Item 1B. Unresolved Staff Comments 47 Item 1C. Cybersecurity 47 Item 2.

Properties

Properties 48 Item 3.

Legal Proceedings

Legal Proceedings 48 Item 4. Mine Safety Disclosures 48 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 49 Item 6. Reserved 49 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 50 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 56 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 56 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 56 Item 9A.

Controls and Procedures

Controls and Procedures 57 Item 9B. Other Information 57 PART III Item 10. Directors, Executive Officers, and Corporate Governance 58 Item 11.

Executive Compensation

Executive Compensation 58 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 58 Item 13. Certain Relationships and Related Transactions, and Director Independence 59 Item 14. Principal Accounting Fees and Services 59 PART IV Item 15. Exhibits, Financial Statement Schedules 60 Item 16. Form 10-K Summary 60 i Cautionary Statement Concerning Forward-Looking Statements This Annual Report on Form 10-K, particularly in Item 1. Business, and Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, and the information incorporated herein by reference, include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on current expectations and beliefs and involve numerous risks and uncertainties that could cause actual results to differ materially from expectations. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. When used in this report, the words "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "indicate," "intend," "may," "plan," "predict," "seek," "should," "target," "will," "would," and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. For example, forward-looking statements include, but are not limited to, statements about: our plans, strategies, and objectives for future operations, including the execution and timing of those plans; our future financial condition or performance, including the accuracy of our estimates re

B usiness

Item 1. B usiness. Business Overview Savara Inc. (together with its subsidiaries "Savara," the "Company," "we," "our" or "us") is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our sole program, molgramostim nebulizer solution ("molgramostim"), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor ("GM-CSF") in Phase 3 development for autoimmune pulmonary alveolar proteinosis ("aPAP"). Molgramostim is delivered via a proprietary eFlow Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. Corporate Strategy Our goal is to become a leader in rare respiratory therapeutics through the development and commercialization of novel, best-in-class medicines that address unmet medical needs in this field. Key elements of our strategy include: Continued advancement of the molgramostim aPAP program and the Phase 3 IMPALA-2 pivotal clinical trial. The IMPALA-2 trial design has been endorsed by regulatory authorities in the U.S. (FDA), Europe (EMA), United Kingdom Medicines and Healthcare Products Regulatory Agency ("MHRA")), and Japan (Pharmaceuticals and Medical Devices Agency ("PMDA")), and regulatory and ethics committees in various countries and sites where the trial is being conducted. The dosing of the first patient was initiated in June 2021. During the second quarter of 2023, patient enrollment in the trial was completed (target enrollment was 160, the trial enrolled 164 patients) with top line results expected to be reported at the end of the second quarter of 2024. Ensuring all aspects of our manufacturing are validated and can produce product at commercial scale. In order to help ensure an uninterrupted drug supply and mitigate approvability risk, we are investing in the establishment of potential s

View Full Filing

View this 10-K filing on SEC EDGAR